- Home
- RLI vs IONS Comparison
RLI vs IONS Comparison
Compare RLI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLI
- IONS
- Stock Information
- Founded
- RLI 1965
- IONS 1989
- Country
- RLI United States
- IONS United States
- Employees
- RLI N/A
- IONS N/A
- Industry
- RLI Property-Casualty Insurers
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- RLI Finance
- IONS Health Care
- Exchange
- RLI Nasdaq
- IONS Nasdaq
- Market Cap
- RLI 6.8B
- IONS 6.4B
- IPO Year
- RLI 1985
- IONS 1991
- Fundamental
- Price
- RLI $71.27
- IONS $42.88
- Analyst Decision
- RLI Hold
- IONS Buy
- Analyst Count
- RLI 8
- IONS 16
- Target Price
- RLI $78.60
- IONS $58.25
- AVG Volume (30 Days)
- RLI 516.6K
- IONS 2.0M
- Earning Date
- RLI 07-21-2025
- IONS 07-31-2025
- Dividend Yield
- RLI 3.65%
- IONS N/A
- EPS Growth
- RLI N/A
- IONS N/A
- EPS
- RLI 3.03
- IONS N/A
- Revenue
- RLI $1,733,218,000.00
- IONS $717,253,000.00
- Revenue This Year
- RLI N/A
- IONS $7.98
- Revenue Next Year
- RLI $5.96
- IONS $16.09
- P/E Ratio
- RLI $23.50
- IONS N/A
- Revenue Growth
- RLI 8.88
- IONS N/A
- 52 Week Low
- RLI $68.50
- IONS $23.95
- 52 Week High
- RLI $91.15
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- RLI 42.76
- IONS 68.29
- Support Level
- RLI $69.16
- IONS $41.22
- Resistance Level
- RLI $72.47
- IONS $43.71
- Average True Range (ATR)
- RLI 1.34
- IONS 1.34
- MACD
- RLI -0.00
- IONS 0.16
- Stochastic Oscillator
- RLI 43.59
- IONS 75.79
About RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.